Toll-Free 1-866-625-9854

Erispan Compuesto (Loratadine, Betamethasone)

Active Ingredient: Loratadine, Betamethasone
Dosage: 100 mg / 5 mg
Route of Administration: Oral
Dosage Form: Solution
Quantity per package: 100 ml

Erispan Compuesto contains Loratadine, Betamethasone. It is prescribed for allergy symptoms’ treatment. Common symptoms are sneezing, runny nose, watery eyes, and etc.

This medicine is currently unavailable but there is a great analog of Erispan Compuesto.


Erispan Compuesto is indicated for the relief of the inflammatory and pruritic manifestations that characterize some atopic dermatosis, angioedema, urticaria, seasonal and perennial allergic rhinitis; food and drug allergic reactions, seborrheic dermatitis, neurodermatitis, allergic asthma, allergic eye manifestations such as conjunctivitis and iridocyclitis and allergic reactions to insect bites.

The purpose of this combination is the elimination of inflammation through the action of betamethasone and pruritus through the action of loratadine.

Dosage and administration

The drug is taken orally. Dose: Children 4 to 6 years of age: Weighing 30 kg or less: Half (½) teaspoon (2.5 ml) twice a day, every 12 hours. Dose: Children 6 to 12 years of age: Weighing more than 30 kg: One teaspoon (5 ml) twice a day, every 12 hours.


Erispan Compuesto is contraindicated in patients with systemic fungal infections and in those with hypersensitivity to any of its components or to drugs of similar chemical structures, pregnancy and lactation.

Side effects

The most commonly reported adverse effects include fatigue; headache; drowsiness; dry mouth; gastrointestinal disorders such as nausea and gastritis; allergic symptoms such as rashes; fluid and electrolyte disorders, sodium retention, loss of potassium, hypocalcemic alkalosis, fluid retention, CHF in sensitive patients and hypertension; musculoskeletal, muscle weakness, corticosteroid myopathy, loss of muscle mass, worsening of myasthenic symptoms in myasthenia gravis; osteoporosis, vertebral fractures, compression, aseptic necrosis of the femoral and humeral heads, pathological fracture of the long bones and tendon rupture; gastrointestinal, peptic ulcer with the possibility of further perforation and bleeding, pancreatitis, abdominal distension and ulcerative esophagitis; dermatological, impaired wound healing, skin atrophy, fragile and thin skin, petechiae and ecchymosis, facial erythema, increased sweating, suppression of reactions such as allergic dermatitis, urticaria and angioneurotic edema; neurological, seizures, increased intracranial pressure with papilledema (cerebral pseudotumor), usually, after treatment, vertigo and headache; endocrine, menstrual irregularities, development of cushingoid status, suppression of intrauterine fetal or childhood growth, lack of secondary response of the adrenal cortex or pituitary, particularly, in times of stress, such as trauma, surgery or condition of enf, reduction of carbohydrate tolerance, manifestations of latent diabetes mellitus, increased requirements of insulin or oral hypoglycemic agents in diabetic patients; ophthalmic, posterior subcapsular cataracts, increased intraocular pressure, glaucoma and exophthalmos; metabolic, negative nitrogen balance due to protein catabolism; psychiatric, euphoria, violent mood swings, from severe depression to frankly psychotic manifestations, personality changes, exaggerated irritability and insomnia; others, anaphylactoid and hypersensitivity reactions and hypotensive or shock-like reactions.


Erispan Compuesto is a combined product, so the potential toxicity of each of its components must be considered. An overdose may cause drowsiness, tachycardia and headache. If necessary, the treatment should be started immediately (symptomatic and adjuvant). Treatment: Vomiting should be induced even if emesis has occurred spontaneously. Vomiting induced pharmacologically with the administration of syrup of ipecac is the preferred method. However, vomiting should not be induced in patients with an altered state of consciousness. Adequate fluid intake should be maintained and serum and urinary electrolytes monitored, paying particular attention to sodium and potassium balance.


Loratadine: an increase in plasma concentrations of loratadine has been reported after concomitant administration of ketoconazole, erythromycin or cimetidine in controlled clinical studies, but no clinically significant changes (including electrocardiographic) have been observed; Precaution should be exercised when other drugs that inhibit liver metabolism are co-administered.

Betamethasone: the concomitant use of phenobarbital, rifampicin, diphenylhydantoin or ephedrine may increase corticosteroid metabolism by decreasing its therapeutic action.

Patients who co-administered a corticosteroid and an estrogen should be observed for the possible increase in corticosteroid effects. Simultaneous administration of corticosteroids with diuretics that cause increased potassium elimination could increase hypokalemia. Concomitant use of corticosteroids with cardiac glycosides may increase the possibility of arrhythmias or digital toxicity associated with hypokalemia. Corticosteroids may increase potassium depletion caused by amphotericin B. Concomitant use of corticosteroids with coumarin-like anticoagulants may increase or decrease the anticoagulant effects, possibly requiring dose adjustment. The combined effects of NSAID drugs or alcohol with corticosteroids could increase the incidence or increase the severity of gastrointestinal ulcers. Corticosteroids can reduce blood salicylate concentrations. The ASA should be used carefully in conjunction with corticosteroids in case of hypoprothrombinemia. When corticosteroids are administered to diabetics, an adjustment of the antidiabetic drug may be required. Concomitant use of corticosteroids with somatropin may inhibit the response to somatropin.

Administration of Erispan Compuesto should be suspended approximately 48 hours before performing skin test procedures since these drugs can prevent or lessen reactions that would otherwise be positive for dermal reactivity indicators. Corticosteroids can alter the results of the tetrazolyl nitro blue test for bacterial infections and produce false ones.